29 related articles for article (PubMed ID: 38652243)
1. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract][Full Text] [Related]
2. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.
Hanke N; Kunz C; Thiemann M; Fricke H; Lehr T
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30939793
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Wei KC; Hsu PW; Tsai HC; Lin YJ; Chen KT; Toh CH; Huang HL; Jung SM; Tseng CK; Ke YX
Sci Rep; 2021 Dec; 11(1):24067. PubMed ID: 34911992
[TBL] [Abstract][Full Text] [Related]
4. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.
Radujkovic A; Boch T; Nolte F; Nowak D; Kunz C; Gieffers A; Müller-Tidow C; Dreger P; Hofmann WK; Luft T
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33302451
[TBL] [Abstract][Full Text] [Related]
5. Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy.
Bond DR; Lee HJ; Enjeti AK
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114584
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
7. Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.
Zaidi SDEZ; Fatima Zaidi SM; Rangwala BS
Ann Hematol; 2024 Jun; 103(6):2163-2164. PubMed ID: 38652243
[No Abstract] [Full Text] [Related]
8. [Myelodysplastic syndromes--clinical and biological features].
Yoshida Y
Gan To Kagaku Ryoho; 1994 Feb; 21(2):135-40. PubMed ID: 8311482
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in myelodysplastic syndromes: ASH 2003 review.
Candoni A; Silvestri F; Buonamici S; Li D; Reddy P; Galili N; Nucifora G; Raza A
Semin Hematol; 2004 Apr; 41(2 Suppl 4):13-20. PubMed ID: 15190511
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
